(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19833 A1

(51) International Patent Classification[7]: C07D 498/04, 519/00, A61K 31/40, 31/55, 31/501, 31/42, 31/44, 31/506, A61P 25/18 // (C07D 498/04, 333:00, 261:00) (C07D 519/00, 498:00, 451:00) (C07D 519/00, 498:00, 495:00)

(21) International Application Number: PCT/US00/24962

(22) International Filing Date:
13 September 2000 (13.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/396,081 14 September 1999 (14.09.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/396,081 (CON)
Filed on 14 September 1999 (14.09.1999)

(71) Applicant *(for all designated States except US)*: **AVENTIS PHARMACEUTICALS, INC.** [US/US]; Route 202-206, P.O. Box 6800, Bridgewater, NJ 08876-0800 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FINK, David, M.** [US/US]; One Kensington Court, Lebanon, NJ 08833 (US). **FREED, Brian, S.** [US/US]; 47 Puddingstone Way, Phillipsburg, NJ 08865 (US). **HRIB, Nicholas, J.** [US/US]; 2402 Jamestown Common, Somerville, NJ 08876 (US). **KOSLEY, Raymond, W., Jr.** [US/US]; 659 Cedarbrook Road, Bridgewater, NJ 08807 (US). **LEE, George, E.** [US/US]; 2 Seville Drive, Somerville, NJ 08876 (US). **MERRIMAN, Gregory, H.** [US/US]; 248 Stonehenge Drive, Phillipsburg, NJ 08865 (US). **RAUCKMAN, Barbara, S.** [US/US]; 21 Barley Sheaf Road, Flemington, NJ 08822 (US).

(74) Agents: **KURYS, Barbara, E.** et al.; Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Mail Code: EMC-G1, Bridgewater, NJ 08807-0800 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*
— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/19833 A1

(54) Title: THIENOISOXAZOLYL- AND THIENYLPYRRAZOLYL-PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D_4 ANTAGONISTS

(57) Abstract: The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D_4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D_4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.